Core Insights - Xianle Health reported a revenue of 3.291 billion yuan for the first nine months of 2025, representing a year-on-year growth of 7.96% [1] - The net profit attributable to shareholders for the same period was 260 million yuan, up 8.53% year-on-year, while the net profit excluding non-recurring items was 244 million yuan, a decrease of 3.42% year-on-year [1] - In Q3 2025, the company achieved a revenue of 1.250 billion yuan, marking an 18.11% increase year-on-year, with a net profit of 99 million yuan, up 16.20% year-on-year [1] Revenue Growth - Q3 2025 saw a significant acceleration in revenue from the domestic market, with income/orders growing by over 20% and 25% respectively, contrasting with a decline of 1.63% in H1 [2] - The new retail customer development remains strong, with revenue from MCN/private domain channels increasing by over 60% in Q3 [2] - The European region also experienced accelerated revenue growth in Q3, with a year-on-year increase of over 35%, compared to 21.96% in H1 [2] Profitability and Cost Management - The overall gross margin for Q3 was 30.76%, an increase of 1.12 percentage points year-on-year, attributed to a higher revenue share from the Americas and an increase in high-margin self-developed products [3] - The selling expense ratio, management expense ratio, and R&D expense ratio for Q3 were 7.72%, 9.55%, and 3.07% respectively, showing slight increases year-on-year [3] - The net profit margin decreased by 0.41 percentage points to 6.85% [3] Future Projections - Based on the performance in the first half of the year, the company maintains a cautious outlook for full-year revenue and profit forecasts, estimating revenues of 4.572 billion, 5.092 billion, and 5.677 billion yuan for 2025-2027, with net profits of 332 million, 423 million, and 504 million yuan respectively [3] - The current market capitalization corresponds to a PE ratio of 21.12x, 16.61x, and 13.92x for the respective years [3]